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INTRODUCTION
The avascular and alymphatic nature of articular car-
tilage coupled with its notably low cell to tissue volume 
ratio are at the core of its limited inherent regenerative 
capacity. Traditional tissue engineering strategies have 
therefore encountered many hurdles but have evolved dra-
matically in the past few decades (1). The latest strategies 
seem to concentrate more on chaperoning regeneration 
rather than tissue replacement (9).  However, we are still 
far from determining a gold standard for cell-based carti-
lage therapeutic strategies with the choice of cell source 
remaining a central and controversial issue. Bone marrow-
derived adult mesenchymal stromal cells (MSCs) have 
lately become the most popular choice due to their multi-
potency and reported immune- modulatory capabilities, 
especially in cases of allogeneic transplantations (8). 
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Articular cartilage regeneration poses particularly tough challenges for implementing cell-based therapies. Many 
cell types have been investigated looking for a balanced combination of responsiveness and stability, yet tech-
niques are still far from defining a gold standard. The work presented focuses on the reliable expansion and 
characterization of a clinical grade human epiphyseal chondroprogenitor (ECP) cell bank from a single tissue 
donation. A parental human ECP cell bank was established, which provides the seed material for master and 
working cell banks. ECPs were investigated at both low and high cumulative population doublings looking at 
morphology, monolayer expansion kinetics, resistance to cryogenic shock, colony-forming efficiency, and cell 
surface markers. Three-dimensional micropellet assays were used to determine spontaneous extracellular matrix 
deposition at varying population doublings and monolayer 2D differentiation studies were undertaken to assess 
the propensity for commitment into other lineages and their stability. ECPs exhibited remarkable homogeneity 
in expansion with a steady proliferative potential averaging three population doublings over 8 days. Surface 
marker analysis revealed no detectable contaminating subpopulations or population enrichment during prolonged 
culture periods. Despite a slight reduction in Sox9 expression levels at higher population doublings in monolayer, 
nuclear localization was equivalent both in monolayer and in micropellet format. Equally, ECPs were capable 
of depositing glycosaminoglycans and producing aggrecan, collagen I, and collagen II in 3D pellets both at low 
and high population doublings indicating a stable spontaneous chondrogenic potential. Osteogenic induction was 
differentially restricted in low and high population doublings as observed by Von Kossa staining of calcified 
matrix, with a notable collagen X, MMP13, and ADAMTS5 downregulation. Rare adipogenic induction was seen 
as evidenced by cytoplasmic lipid accumulation detectable by Oil Red O staining. These findings highlight the 
reliability, stability, and responsiveness of ECPs over prolonged culture, making them ideal candidates in defining 
novel strategies for cartilage regeneration.
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Concerns of homogeneity, reliability, and  stability still 
predominate current investigations (17). For instance, 
MSCs may present markers of chondrogenesis when 
stimulated by potent recombinant morphogens, particu-
larly from the transforming growth factor (TGF)-b super-
family. The forced differentiation process, however, often 
evolves into a phenotypic overshoot by recapitulating 
endochondral ossification (11). These often observed insta-
bilities and heterogeneous cellular responses have moti-
vated some groups to propose extensive cell sorting and 
population enrichment protocols in an effort to normal-
ize results and reduce donor variability (13,18,21). These 
hurdles have made adult MSCs very difficult to control 
for applications in cartilage tissue regeneration. 
In a microenvironment as damaged and unstable as that 
of osteoarthritic cartilage, the need for a responsive yet 
stable therapeutic cell type is a key element. Fetal cartilage 
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has been shown to exhibit a  remarkable ability for self-
repair (15), and much like other progenitor and stem cell 
types, fetal cells appear to exhibit  immune-modulatory 
activity (14,20). Human  epiphyseal  chondroprogenitors 
(ECPs) therefore  present distinct advantages by having 
both a prededicated  tissue-specific repertoire of differ-
entiation potential and fine-tuned  sensitivity to rapidly 
changing  environmental cues during the course of natural 
tissue growth and maturation. Compared with isolated 
quasi-quiescent adult chondrocytes normally found 
embedded in the adult tissue, ECPs would theoretically 
exhibit superior stability in withstanding environmental 
variability. ECPs would also  maintain a commitment to 
their differentiation  program, one that necessitates an 
inherent mild plasticity, allowing them to modulate their 
response to varying micro environments. 
The work presented here focuses on the characterization 
of a human ECP cell bank from a single tissue donation 
produced within a federally registered transplantation pro-
gram in Switzerland. These results reported herein mark 
the first step in defining an ECP-based cellular therapy 
strategy for cartilage regeneration, which could be used in 
early degenerative joint indications or cell therapy-assisted 
surgeries such as microsurgeries of the hand.
maTERIalS aND mETHODS
Tissue Processing and Cell Banking
Human ECPs were isolated from the proximal ulnar 
 epiphysis of a 14-week gestation donor (Centre Hospitalier 
Universitaire Vaudois Ethics Committee Protocol #62/07). 
The procedure mirrored that used by our group for fetal 
skin fibroblasts (19). Briefly, the tissue biopsy was micro-
dissected and mechanically dispersed. ECP outgrowth 
was observed at 1 week (Fig. 1A) and expansion was 
accomplished at 2 weeks in Dulbecco’s modified Eagle 
medium (DMEM) with 25 mM dextrose, 1 mM sodium 
pyruvate, 5.97 mM l-glutamine, and 10% clinical grade 
fetal bovine serum (Invitrogen, Glasgow, Scotland), free 
of antibiotic supplementation. The parental cell bank was 
established with 100 vials of 5–10 × 10 6 cells and stored 
in the vapor phase of liquid nitrogen, providing cells for 
a working cell bank dedicated to in vitro investigations 
as well as cells for in vivo validations down the line. All 
cell culture media and supplements were purchased from 
Invitrogen, Life Technologies Ltd. (Paisley, UK), unless 
otherwise noted.
Cell Expansion and Culture
Monolayer expansions were performed in standard 
tissue culture polystyrene flasks in basal media con-
taining DMEM with 25 mM dextrose, 1 mM sodium 
pyruvate, 5.97 mM l-glutamine, and 10% fetal bovine 
serum (Sigma, St. Louis, MO), free of antibiotic 
supplementation. ECPs were seeded at 4,000 cells/cm2, 
placed in standard humidified tissue culture incubators at 
37°C with 5% CO2, and passed after reaching 90% con-
fluence following two media changes over an average of 
9 days per passage. 
Proliferation, Viability, and Recovery
The Cell Titer 96 Aqueous One Solution Cell Pro-
liferation Assay (Promega, Fitchburg, WI) was used to 
monitor proliferation kinetics in basal media on standard 
tissue culture polystyrene at 2, 4, 6, 8, 10, 12, and 14 
days. This was performed on ECPs after 9 and 18 cumulative 
population doublings (PDs) to evaluate potential losses 
in proliferative potential. The 490-nm absorbance values, 
which correlate with the amount of  metabolically active 
cells, were read using the Wallac VICTOR2™ 1420 multi-
label plate reader (PerkinElmer, Waltham, MA). The sta-
bility of cells was assessed after freezing and stocking of 
ECPs. Vials from the working cell bank containing 2 million 
cells/ml, previously cryopreserved in an isopropanol bath 
at –80°C overnight then transferred and stocked in liquid 
nitrogen for 3 years, were thawed in a 37°C water bath. 
The LIVE/DEAD® viability/cytotoxicity staining kit 
(Invitrogen, Life Technologies Ltd., Paisley, UK) was used 
to quantify live and dead cells immediately after thawing 
by tracking green fluorescent calcein-AM-positive live 
cells and red fluorescent ethidium homodimer-1-positive 
dead cells using the BD Accuri® C6 flow cytometer and 
CFlow® software for analysis (Accuri® Cytometers, Ann 
Arbor, MI). To evaluate the plating efficiency following 
thawing, cells were seeded onto standard tissue culture 
polystyrene for 24 h in basal media. The remaining floating 
cells, both live and dead, were quantified in a standard 
counting chamber using Trypan blue exclusion.
Surface Marker Profiling
Surface marker detection was performed on ECPs 
after 9 and 24 cumulative PDs to assess population stabil-
ity and homogeneity. ECP surface markers were detected 
using monoclonal mouse antibodies specific for human 
CD14, CD26, CD34, CD44, CD90, CD105, and CD166 
(Abd Serotec, Dusseldorf, Germany) in combination with 
an AlexaFluor® 488 goat anti-mouse IgG polyclonal anti-
body (Invitrogen, Life Technologies Ltd., Paisley, UK). 
Equally, phycoerythrin-tagged monoclonal CD45, CD73, 
and human leukocyte antigen (HLA)-DP,DQ,DR antibodies 
as well as fluorescein-tagged HLA-A,B,C
 
antibodies were 
also used (R&D Systems, Minneapolis, MN).
 Appropriate 
isotype controls with equivalent concentrations were used 
to determine nonspecific staining. Ethidium bromide 
monoazide (Sigma, St. Louis, MO) was used to detect and 
exclude cells with damaged membranes. The CyAN™ 
ADP analyzer (Beckman Coulter, Indianapolis, IN) was 
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used to perform flow cytometry assays, and FlowJo soft-
ware (Ashland, OR) was used for analysis. 
Spontaneous Chondrogenesis
After 9 and 18 cumulative PDs, micropellets were 
formed by centrifuging 5 ´  105 cells in Nunc U96 Micro-
Well™ plates (Thermo Fisher Scientific, Waltham, MA) 
at 500 ´  g for 5 min and maintained in 200 µl serum-
free media containing DMEM with 25 mM dextrose, 
1 mM sodium pyruvate, 5.97 mM l-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 1% insulin-transferrin-
 selenium (ITS), and 50 µg/ml l-ascorbate (Sigma, St. 
Louis, MO), with three medium changes per week. ECPs 
micropellets formed after 9 PDs were harvested for 
analysis after 17 days in culture to reveal the presence 
of spontaneously expressed chondrogenic markers. ECP 
micropellets formed after 18 PDs were harvested after 
27  days to allow for more matrix deposition as the pellets 
had not reached the equivalent size of their 9 PD counter-
parts by 17 days.
Micropellets were fixed in 4% paraformaldehyde for 
2 h at room temperature, washed thoroughly with phos-
phate-buffered saline (PBS), dehydrated, and embedded 
in paraffin (Merck, Whitehouse Station, NJ). Sections 
of 5 µm in thickness were then rehydrated and stained 
with Alcian blue (Merck, Whitehouse Station, NJ) to 
detect glycosaminoglycan deposits and a nuclear fast red 
counterstain (Bio-Optica, Milan, Italy) to highlight cells. 
Micropellet sections were also processed for immuno-
histochemistry, screening for chondrogenic mark-
ers. Samples underwent heat-mediated antigen retrieval 
for 20 min at 95°C in 10 mM trisodium citrate buffer 
(pH 6). Intracellular sex-determining region y box 9 
(Sox9) staining required 20-min incubation in 0.25% 
Triton X in PBS prior to primary antibody tagging over-
night at 4°C with a mouse anti-human Sox9 monoclonal 
Figure 1. Epiphyseal chondroprogenitor (ECP) outgrowth from the original tissue biopsy after 1 week in culture (A). ECPs exhib-
iting homogenous spindle like morphology in subconfluent (B) and confluent (C) culture conditions. Proliferation kinetics seeded after 
9 and 18 PDs following passage (D) or freshly thawed after long-term cryopreservation in liquid nitrogen (E). Scale bars: 100 µm.
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antibody (0.70 µg/ml, ab76997, Abcam, Cambridge, UK). 
Secondary tagging was performed at room temperature 
with AlexaFluor® 488 goat anti-mouse IgG polyclonal 
antibody (1:1,000, Invitrogen, Life Technologies Ltd., 
Paisley, UK) and mounted using Vectashield® mounting 
medium with DAPI (Vector Laboratories, Burlingame, 
CA). Aggrecan staining required a 30-min hyaluronidase 
(2 mg/ml, Sigma, St. Louis, MO) treatment at 37°C 
before applying the primary mouse anti-human aggrecan 
monoclonal antibody (1:100, AHP0022, Invitrogen, Life 
Technologies Ltd., Paisley, UK). Collagen II staining 
required a treatment with chondroitinase-ABC (0.25 U/ml, 
Sigma, St. Louis, MO) at 37°C for 1 h before applying 
the primary mouse anti-human collagen II mono clonal 
antibody (1:100, ab3092, Abcam, Cambridge, UK). 
Collagen I was stained using a primary rabbit anti-human 
collagen I polyclonal antibody (1:200, ab292, Abcam, 
Cambridge, UK). After an incubation overnight at 4°C, 
the ImmPRESS anti-mouse Ig or anti-rabbit Ig system 
(Vector Laboratories, Burlingame, CA) was used followed 
by peroxidase revelation with DAB (Vector Laboratories, 
Burlingame, CA). 
Multilineage Differentiation
After 9 and 18 cumulative PDs, ECPs were plated onto 
standard tissue culture 12-well plates, grown in basal 
media until reaching 50% confluence and then kept in 
differentiation media with changes three times per week. 
ECPs were subjected to adipogenic culture conditions 
over 27 days in DMEM with 25 mM dextrose, 1 mM 
sodium pyruvate, 5.97 mM l-glutamine, 1% ITS, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 1 µM dexamethasone, 
100 µM 3-isobutyl-1-methyl-xanthine (Sigma, St. Louis, 
MO), and 100 µM indomethacine (Sigma, St. Louis, MO) 
to evaluate potential adipogenesis. Cells were then fixed 
in 4% paraformaldehyde for 15 min at room temperature, 
washed in PBS, and stained using Oil Red O to reveal 
cytoplasmic lipid deposits.
Cells were also monitored over 21 days in terminally 
differentiating osteogenic media consisting of DMEM 
with 25 mM dextrose, 1 mM sodium pyruvate, 5.97 mM 
l-glutamine, 10% fetal bovine serum, 100 U/ml penicil-
lin, 100 µg/ml streptomycin, 50 µg/ml l-ascorbate, 10 mM 
b-glycerophosphate (Sigma, St. Louis, MO), and 10 nM 
dexamethasone (Sigma, St. Louis, MO). Cells subjected 
to osteogenic induction were fixed in 4% paraformalde-
hyde for 15 min at room temperature, washed in PBS, 
and processed following standard Von Kossa staining 
procedure to reveal calcified nodules. Total RNA isola-
tion was also performed using the Nucleospin® RNA/protein 
extraction kit (Macherey-Nagel, Dueren, Germany). 
Total RNA was primed with random hexamers, and 
cDNA was produced using Taqman® reverse transcription 
reagents from Applied Biosystems, Life Technologies Ltd. 
(Paisley, UK). Quantitative PCR was performed using 
the Fast SyBR® Green PCR Master Mix from Applied 
Biosystems, Life Technologies Ltd. (Paisley, UK) as 
well as primers synthesized by Microsynth (Balgach, 
Switzerland) for collagen type X alpha 1 (Col10a1; 
F: 5¢-TGCTAGTATCCTTGAACTTGGTTCAT-3¢; 
R: 5¢- CTGTGTCTTGGTGTTGGGTAGTG-3¢) (16), mat- 
rix metalloproteinase 13 (MMP13; F: 5¢-CCTCCAGTTT 
GCAGAGCGCTACC-3¢; R: 5¢-TCTCCTTCAGGATTC 
CCGCGAGA-3¢), A disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTS5; F: 5¢-ACG 
ATGCCACCCAGCAGTGC-3¢; R: 5¢-ACAGCACACC 
ACAGGCGAGC-3GCCACCCAGCAGTG), and the 
housekeeping gene b2 microglobulin (B2M) (F: 5¢- 
GCATTCGGGCCGAGATG-3¢; R: 5¢-AATCTTTGG 
AGTACGCTGGATAGC-3¢). Gene expression data were 
processed following the comparative Ct method, normal-
izing gene expression levels by that of the housekeeping 
gene and using as a biological reference the normalized 
gene expression levels from cells grown after 9 PDs in 
basal media until confluence.
Statistical Analyses
Proliferation and gene expression data are represented 
as means (n = 3), with error bars showing standard devia-
tions. Gene expression levels were analyzed statistically 
using Student’s t test where p < 0.05 indicated statistically 
detectable differences. 
RESUlTS
Growth Kinetics and Behavior
Isolated ECPs exhibited a remarkable morphological 
homogeneity in monolayer culture (Fig. 1B, C). Cells 
retained the same morphology and homogeneity after 18 
PDs. ECP growth kinetics were equivalent at relatively 
low (9) and high (18) PDs (Fig. 1D), with a notably stable 
proliferative potential averaging 2.9 ± 0.3 (mean ± SD) 
PDs every 9 days up to 24 PDs. The same stability is 
observed after cryogenic preservation and thawing, albeit 
with an observed slower onset of proliferation at later pas-
sages or PDs (Fig. 1E). The plating efficiency of freshly 
thawed cells after prolonged storage in liquid nitrogen 
was maintained at 86% with an initial viability between 
82% and 90% for cells frozen after 6 and 18 PDs.
Homogeneous and Stable Surface Marker Profiles
Surface marker detection revealed stable population 
homogeneity for all tested markers at 9 PDs (Fig. 2A) 
and 24 PDs (Fig. 2B) with no discernible subpopula-
tion enrichment. The same pattern was observed at 18 
PDs (data not shown). The ECP population does not 
contain potentially contaminating cell types as seen by 
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Figure 2. Surface marker profiles reveal homogenous populations for ECPs throughout growth to 9 PDs (A) or 24 PDs (B). Tinted red histo-
grams are indicative of the tagged population, and empty black histograms represent isotype controls for each cell surface marker. Scatter 
plots show 5% population density contours with dots representing outliers. CD, cluster of differentiation; HLA, human leukocyte antigen.
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the negative markers CD14, CD34, CD45, and HLA-
DP,DQ,DR. ECPs appear to be distinctly positive for 
CD44, CD73, CD90, CD105, and CD166 and mildly 
positive for CD26 and HLA-A,B,C. The latter may be 
indicative of an immune privilege such as that present in 
adult MSCs. Since chondrocytes do not present a specific 
surface marker and in fact share many positive mark-
ers with adult bone marrow-derived MSCs, analyzing 
the relative surface marker profiles consistent of ECPs 
yielded a chondrogenic (CD90 bright, CD105 dim) rather 
than an undifferentiated stem-like phenotype (CD90 
dim, CD105 bright) (6). Equally, CD105 levels were 
maintained throughout PDs, possibly indicating a delay 
in dedifferentiation, a particularly problematic aspect of 
adult chondrocyte monolayer expansions. 
Spontaneous Chondrogenic Potential
ECPs were cultured in three-dimensional micropellets 
in a medium devoid of growth factors (free of serum-
bound or recombinant growth factors) to assess their 
spontaneous chondrogenic potential. The nuclear local-
ization pattern of the transcription factor Sox9, a known 
master regulator of chondrogenesis, was equivalent in 3D 
micropellet cultures for cells after 9 and 18 PDs (Fig. 3). 
The 18 PD pellets were left for an additional 10 days in 
culture to allow more matrix deposition. Both low and 
high PD micropellets showed a distinctive glycosamino-
glycan deposition with aggrecan deposits concentrated in 
clusters. Collagen I deposition was seen throughout the 
pellet agglomeration while collagen II deposition was 
only pericellular, an expected pattern for fetal cartilage 
Figure 3. Spontaneous chondrogenesis in micropellets performed following 9 PDs and grown in serum-free media for 17 days (A–E) 
as well as pellets following 18 PDs and grown in serum-free media for 27 days (F–J). Sox9 nuclear localization is visualized in red 
overlapped with DAPI stained nuclei in blue (A, F). Glycosaminoglycan (GAG) deposition is visualized in blue after Alcian blue stain-
ing with a nuclear fast red counterstain to reveal cells (B, G). Immunohistochemical staining of human aggrecan (C, H), collagen I 
(D, I), and collagen II (E, J) is revealed using a DAB peroxidase substrate in brown with the respective background staining repre-
sented in smaller cropped panels at the same scale. Scale bars: 100 µm.
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cells and tissues that are loosely cross-linked to allow for 
rapid development and remodeling during morphogen-
esis (3). This type of primary matrix produced by ECPs 
may therefore help harbor the cells within a cartilage 
defect during the early stages of regeneration before de 
novo tissue maturation occurs.
Restricted Multilineage Plasticity
A relatively aggressive adipogenic differentiation pro-
tocol over 27 days generated very few cells with cyto-
plasmic lipid accumulation (an average of 1 cell per 
34,000) (Fig. 4A). The same behavior was observed both 
after 9 and 18 PDs. Terminally differentiating osteogenic 
induction over 21 days was able to induce minor matrix 
calcification at 9 PDs (Fig. 4B). Induced cells at 18 PDs 
exhibited a delay in differentiation with no detectable 
matrix calcification after 21 days (Fig. 4C). The differ-
entiation towards this path was, however, restricted at 9 
and 18 PDs as observed by the downward trend in expres-
sion for collagen X (a short chain collagen produced by 
hypertrophic chondrocytes) (Fig. 4D) and ADAMTS5 (a 
potent disintegrin and metalloproteinase with thrombos-
pondin motifs that cleaves aggrecan, a fundamental pro-
teoglycan in cartilage) (Fig. 4E), as well as an unchanged 
basal expression of MMP13 (matrix metalloproteinase 13 
or collagenase 3) (Fig. 4F). Stronger downregulation trends 
were observed after 18 PDs for collagen X and ADAMTS5 
along with an inherent baseline decrease in MMP13. These 
three markers, often present in osteoarthritic cartilage, are 
strong indicators of chondrocyte terminal differentiation 
Figure 4. Adipogenic differentiation yields 1 in 34,000 cells with distinctive cytoplasmic lipid depo-
sition visualized in red using the Oil Red O stain. Scale bar: 100 µm. (A) Terminally differentiation 
osteogenic induction yields calcified nodules visualized in brown–black using Von Kossa staining in 
cells after 9 PDs (B) but not after 18 PDs (C). Gene expression levels for COL10A1 (D), ADAMTS5 
(E), and matrix metalloproteinase 13 (MMP13; F) are represented for cells grown in basal media (blue) 
as well as those subjected to 21 days of osteogenic induction (red). Gene expression levels in cells with 
low and high PDs are represented with the data normalized to the housekeeping gene, b-2 microglob-
ulin, and represented as a fold difference relative to normalized gene expression levels in 9 PD cells 
grown in basal media as a biological basal reference. *Statistically detectable differences (p < 0.05).
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and hypertrophy. Their upregulation could indicate the 
beginning stages of cartilage calcification or endochon-
dral ossification, both tightly regulated processes present 
in the growth plate and the deep zone in mature articular 
cartilage. A cell type that readily displays these  markers 
would not be able to maintain a stable chondrogenic pheno-
type and would inadvertently produce a hyper trophic, 
calcified tissue (10,24,25). As expected, collagen II 
expression was undetected in monolayer cultures (data 
not shown). The differentiation cocktail used to induce 
these reported effects did not contain any recombinant 
morphogen supplementation to better assess the inherent 
osteochondral plasticity of ECPs, which was found to be 
restricted. This was also the case using higher levels of 
dexamethasone resulting in low collagen X expression 
levels as well (data not shown). 
DISCUSSION
A common limitation in cartilage cell therapy has 
always been cell number and the expansion potential of 
therapeutic cells, all the while maintaining a stable, reli-
able, and homogenous cell population. Adult cell dedi-
fferentiation or early onset of senescence may occur at 
early passages, a behavior difficult to estimate in PDs 
with the heterogeneity observed in adult stem cells and 
adult chondrocytes primary culture processing. Indeed, as 
adult chondrocytes possess a very slow natural turnover 
rate in vivo, the ex vivo expansion of these adult cells has 
been shown to cause an accelerated aging process equiva-
lent to 30 years after merely 3 PDs. The drastic variability 
observed between donors is also a fundamental hurdle to 
guaranteeing a positive clinical outcome since the quality 
of harvested cells has been reportedly difficult to deter-
mine (4,12,22,26). The observed behavior of ECPs, a com-
bination of stable and predictable growth kinetics as well 
as resilience to the shock often associated with cryogenic 
preservation, makes it possible to scale out the produc-
tion of such cells without compromising quality. We have 
observed similar advantages with fetal skin fibroblasts 
processing and have shown that the  therapeutic potential 
from a 1 cm2 skin biopsy can produce at least 35 ´  109 bio-
logical constructs of 102 cm2 for the treatment of burns 
and wounds.  This type of management of cell banks can 
thus provide clinical material for hundreds of thousands 
of patients (2). This aspect becomes especially important 
when the cell banking process focuses on maximizing 
potential therapeutic yields from one biopsy versus alter-
native strategies such as multiple-donor pooling. 
At 14 weeks of gestation, human long-bone  epiphyses 
are well defined anatomically from the underlying and 
calcifying growth plate, with a notably homogenous 
outlook as secondary ossification has not yet occurred. 
This aspect, along with meticulous biopsy processing, is 
apparent through the unimodal, narrow population surface 
marker profiles of ECPs, indicating homogeneity with 
cells maintaining steady surface marker profiles throughout 
PDs with no apparent subpopulation enrichment. 
This phenotypic stability is further supported by a spon-
taneous chondrogenic potential in ECPs, stable up to 18 
PDs. This comes as a striking and essential advantage over 
undifferentiated, uncommitted stem cells, which require a 
plethora of growth factors to generate a tissue-specific pheno-
type. With stem cell differentiation protocols often gen-
erating unpredictable phenotypic instability (7), working 
with a prededicated cell type such as ECPs avoids the need 
for cell priming and preconditioning prior to implantation. 
The resistance of ECPs to multilineage differentiation such 
as adipogenesis for instance further supports the need for a 
predictable outcome in vivo rather than a situation in which 
implanted cells may affect off-target host tissues.
ECPs were also capable of modulating the quality of 
deposited matrix, forming small, calcified nodules in the 
presence of subtle changes in surrounding environment, 
much like those occurring in full thickness carti lage 
defects. The observed restricted osteogenic or terminally 
differentiating potential is a major advantage when con-
sidering cartilage cell therapy as it indicates ECPs capable 
of responding to cues from various osteo chondral regions. 
A better understanding of their differentiation repertoire will 
best be investigated in vivo where microenvironments 
are finely tuned and difficult to replicate in vitro.
Implanting ECPs in vivo would undoubtedly allow 
novel interactions to occur between the implanted cells and 
the host tissue, which will inform the way the implantation 
must occur to deliver the best outcome and best interaction 
with the degenerated tissue. Previous studies on fetal bone 
and skin cells suggest an immune privilege or immuno-
regulatory functions (14,20). Fetal cells have in fact been 
described to reside in maternal tissues for decades after 
pregnancy and potentially participate in repair of  maternal 
injuries (23). Furthermore, some fetal tissues have been 
found to produce HLA-G, which has been shown to pos-
sess tolerogenic effects (5). ECPs may indeed employ 
various mechanisms to redefine the immune microenviron-
ment in the implanted site, which may help regulate repair 
or reduce inflammation, especially in the days following 
implantation. Such interactions will have to be thoroughly 
investigated in vivo to best predict the efficiency and regen-
erative potential of ECPs.
In conclusion, this work investigates the reliable expansion 
of epiphyseal chondroprogenitors for developing a carti-
lage repair strategy using cells with marked advantages 
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over adult chondrocytes or adult stem cells. The core ECP 
properties shown, such as their stability, homogene-
ity,  spontaneous chondrogenic potential combined with a 
restricted plasticity for terminally differentiating osteogenic 
induction as well as adipogenic induction, are some of the 
major advantages with this cell type.
The estimation of therapeutic applications for cell 
banking of ECPs from one single organ donation, based 
on the characterization to date, would be approximately 
108 treatments when compared with similar clinical use 
and cell numbers from cell therapies based on autologous 
chondrocytes or bone marrow-derived MSCs in current 
cartilage regeneration regimens. Furthermore, ECPs exhib-
iting such phenotypic stability would not require in vitro 
cell priming or conditioning prior to implantation in vivo, 
which drastically facilitates the transition to preclinical 
studies.
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